Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-06-03 Regulatory Filings
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release" at the end and contains key highlights about the company's ten-year anniversary, CEO commentary, and government support, rather than comprehensive financial statements (like 10-K or IR) or detailed Q&A (CT). It announces a specific event and provides context on the company's progress and products. This format strongly aligns with an Earnings Release (ER), which typically announces key period results or significant corporate milestones, even if this specific one celebrates an anniversary rather than quarterly numbers. Since it is a formal announcement of corporate news, ER is the most appropriate fit among the specific categories, as it is not a full report, a presentation, or a management discussion.
2016-06-03 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is titled with a headline celebrating an anniversary and contains quotes from the CEO and government officials, concluding with contact information and standard forward-looking statements. The footer explicitly labels the document as a "Communiqué de presse" (Press Release). This format, which announces company news (in this case, a 10-year anniversary celebration and business updates) rather than presenting formal, periodic financial statements (like 10-K or IR), aligns best with an Earnings Release (ER) if it contained financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement. Since it is a press release announcing corporate news and milestones, and not a formal financial report, the most appropriate general category for a non-standard, non-periodic corporate announcement that isn't a specific event like a dividend or management change is RNS (Regulatory Filings/General Announcement). However, given the content is a general corporate update/celebration, and not strictly a regulatory filing in the SEC sense, but rather a public announcement, it is often categorized as a general press release. Since 'ER' is for financial results highlights, and this is a general corporate milestone announcement, RNS is the best fit among the provided options for a general corporate press release that doesn't fit a more specific category like DIV, MANG, or CAP. The length (8529 chars) is substantial, indicating it is the full content, not just a short RPA notice.
2016-06-03 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is dated May 19, 2016, and is titled "Information réglementée" (Regulated Information). It announces a strategic shift regarding the company's osteoporosis program, substituting the autologous product PREOB® with the allogeneic product ALLOB® and planning a Phase II trial. It includes commentary from the CEO, scientific background, and market context. Crucially, it ends by stating: "Parallèlement à cette annonce, la Société a actualisé son document de présentation. Celui-ci est disponible sur le site web de Bone Therapeutics..." This indicates the primary purpose is to announce a strategic/clinical update, not to release full periodic financial results (like 10-K or IR) or a transcript. Since it details strategic business and clinical development updates, it aligns best with an Investor Presentation (IP) or a general regulatory announcement. Given the detailed strategic update and the mention of an updated presentation, 'Investor Presentation' (IP) is a strong candidate, but since this text itself is the announcement *about* the strategy and the presentation is linked separately, it functions as a significant corporate update. However, the content is highly focused on clinical strategy and future plans, which often accompanies or is part of an Investor Presentation. Since it is a formal announcement of strategic direction and clinical trial plans, and not a standard earnings release (ER) or a comprehensive quarterly report (IR), it fits the profile of an Investor Presentation (IP) or a general Regulatory Filing (RNS). Because it contains substantial strategic information intended for investors, IP is more specific than RNS. If the document were just a short notice saying 'Presentation attached,' it would be RPA. Since it contains the substance of the update, IP is appropriate.
2016-05-19 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 19, 2016, announcing a strategic shift in Bone Therapeutics' development plan for its severe osteoporosis program, specifically transitioning from the autologous product PREOB® to the allogeneic product ALLOB®. It details recent clinical data, management commentary, market context, and future trial plans. This content structure—a formal announcement of business/clinical strategy updates, often including financial context or operational changes, released to the public and regulated entities—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on strategic operational changes and clinical data updates rather than just summarizing period-end results (ER) or being a miscellaneous regulatory notice (RNS), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the context of strategic business updates and clinical progress announcements, and lacking explicit quarterly/annual financial statements, it most closely resembles an Earnings Release (ER) which often contains operational highlights, or a general Regulatory Filing (RNS). However, because it is a detailed announcement of a significant strategic pivot supported by preliminary data, it functions as a major operational update. In many databases, such detailed strategic announcements are classified under ER if they are periodic, or RNS if they are ad-hoc. Since it is not a full financial report (10-K, IR) and is more substantial than a simple dividend notice or management change, and it is not explicitly an Investor Presentation (IP), the most appropriate classification for a significant, non-financial-statement-focused operational update is often ER or RNS. Given the depth of the clinical data discussion, it leans towards an Earnings Release context, even if not explicitly tied to a quarterly close. If we must choose the most specific category for a major operational/clinical update announcement, ER is often used for such substantive news. If it were purely a regulatory filing without the business context, RNS would be better. I will classify it as an Earnings Release (ER) as it contains significant operational and clinical progress updates typically bundled with earnings announcements, though RNS is a close second.
2016-05-19 English
Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
Regulatory Filings Classification · 95% confidence The document is a press release dated May 19, 2016, announcing a strategic shift in Bone Therapeutics' development plan for its severe osteoporosis program, specifically transitioning from the autologous product PREOB® to the allogeneic product ALLOB®. It details recent clinical data, management commentary, market context, and future trial plans. This content structure—a formal announcement of business/clinical strategy updates, often including financial context or operational changes, released to the public and regulated entities—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on strategic operational changes and clinical data updates rather than just summarizing period-end results (ER) or being a miscellaneous regulatory notice (RNS), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general announcement. Given the context of strategic business updates and clinical progress announcements, and lacking explicit quarterly/annual financial statements, it most closely resembles an Earnings Release (ER) which often contains operational highlights, or a general Regulatory Filing (RNS). However, because it is a detailed announcement of a significant strategic pivot supported by preliminary data, it functions as a major operational update. In many databases, such detailed strategic announcements are classified under ER if they are periodic, or RNS if they are ad-hoc. Since it is not a full financial report (10-K, IR) and is more substantial than a simple dividend notice or management change, and it is not explicitly an Investor Presentation (IP), the most appropriate classification for a significant, non-financial-statement-focused operational update is often ER or RNS. Given the depth of the clinical data discussion, it leans towards an Earnings Release context, even if not explicitly tied to a quarterly close. If we must choose the most specific category for a major operational/clinical update announcement, ER is often used for such substantive news. If it were purely a regulatory filing without the business context, RNS would be better. I will classify it as an Earnings Release (ER) as it contains significant operational and clinical progress updates typically bundled with earnings announcements, though RNS is a close second.
2016-05-19 English
Bone Therapeutics développe le potentiel thérapeutique de son programme « ostéoporose sévère » en substituant le produit allogénique ALLOB® à PREOB®
Regulatory Filings Classification · 95% confidence The document is dated May 19, 2016, and is titled "Information réglementée" (Regulated Information). It announces a strategic shift regarding the company's osteoporosis program, substituting the autologous product PREOB® with the allogeneic product ALLOB® and planning a Phase II trial. It includes commentary from the CEO, scientific background, and market context. Crucially, it ends by stating: "Parallèlement à cette annonce, la Société a actualisé son document de présentation. Celui-ci est disponible sur le site web de Bone Therapeutics..." This indicates the primary purpose is to announce a strategic/clinical update, not to release full periodic financial results (like 10-K or IR) or a transcript. Since it details strategic business and clinical development updates, it aligns best with an Investor Presentation (IP) or a general regulatory announcement. Given the detailed strategic update and the mention of an updated presentation, 'Investor Presentation' (IP) is a strong candidate, but since this text itself is the announcement *about* the strategy and the presentation is linked separately, it functions as a significant corporate update. However, the content is highly focused on clinical strategy and future plans, which often accompanies or is part of an Investor Presentation. Since it is a formal announcement of strategic direction and clinical trial plans, and not a standard earnings release (ER) or a comprehensive quarterly report (IR), it fits the profile of an Investor Presentation (IP) or a general Regulatory Filing (RNS). Because it contains substantial strategic information intended for investors, IP is more specific than RNS. If the document were just a short notice saying 'Presentation attached,' it would be RPA. Since it contains the substance of the update, IP is appropriate.
2016-05-19 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.